Simianti Yaowu Overview
- Year Founded
-
2021
- Status
-
Private
- Latest Deal Type
-
Series A1
- Investors
-
4
Simianti Yaowu General Information
Description
Developer and manufacturer of new small molecule drugs intended for the treatment of super-resistant bacteria and malignant tumors. The company has built an advanced technology platform for the development of new drugs against drug-resistant bacteria and a technology platform for the development of new drugs against drug-resistant tumors, providing innovative drug solutions for medical users and patients.
Contact Information
Website
www.cdsimianti.comCorporate Office
- Room 701, 702, Building 2, No. 366, Hemin Street
- Chengdu Hi-tech Zone, China Pilot Free Trade Zone
- Chengdu, Sichuan 610200
- China
Corporate Office
- Room 701, 702, Building 2, No. 366, Hemin Street
- Chengdu Hi-tech Zone, China Pilot Free Trade Zone
- Chengdu, Sichuan 610200
- China
Simianti Yaowu Timeline
Simianti Yaowu Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series A1) | 24-Apr-2025 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 12-Nov-2024 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 07-Nov-2023 | Completed | Generating Revenue | |||
| 1. Secondary Transaction - Private | 23-Dec-2022 | $200K | Completed | Generating Revenue |
Simianti Yaowu Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Simianti Yaowu Patents
Simianti Yaowu Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4759816-A1 | Urea-containing tricyclic ß-lactamase inhibitor, preparation method therefor and use thereof | Pending | 08-Aug-2023 | ||
| JP-2026528821-A | Urea-containing tricyclic β-lactamase inhibitor, method of preparation thereof, and its uses | Pending | 08-Aug-2023 | ||
| AU-2024322286-A1 | Urea-containing tricyclic β-lactamase inhibitor, preparation method therefor and use thereof | Pending | 08-Aug-2023 | ||
| WO-2025031214-A1 | Urea-containing tricyclic β-lactamase inhibitor, preparation method therefor and use thereof | Inactive | 08-Aug-2023 | C07D471/18 |
Simianti Yaowu Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Huaxi Yinfeng Investment | Corporate Venture Capital | Minority | ||
| Suzhou Industrial Park Value Capital | Growth/Expansion | Minority | ||
| Suzhou Innovation Investment Group | Venture Capital | Minority | ||
| Neijiang Technology Development | VC-Backed Company | Minority |
Simianti Yaowu FAQs
-
When was Simianti Yaowu founded?
Simianti Yaowu was founded in 2021.
-
Where is Simianti Yaowu headquartered?
Simianti Yaowu is headquartered in Chengdu, China.
-
What industry is Simianti Yaowu in?
Simianti Yaowu’s primary industry is Drug Discovery.
-
Is Simianti Yaowu a private or public company?
Simianti Yaowu is a Private company.
-
What is Simianti Yaowu’s current revenue?
The current revenue for Simianti Yaowu is .
-
How much funding has Simianti Yaowu raised over time?
Simianti Yaowu has raised $1.4M.
-
Who are Simianti Yaowu’s investors?
Huaxi Yinfeng Investment, Suzhou Industrial Park Value Capital, Suzhou Innovation Investment Group, and Neijiang Technology Development have invested in Simianti Yaowu.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
